Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the occurrence, timing and pace of future clinical trials, the belief that ANA598 has the potential for beneficial combination with several other anti-HCV agents, the anticipated future clinical benefits of ANA598 and ANA773 and expectations regarding cash utilization. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Conden
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... its 2015 Annual Meeting of Stockholders on May 4, ... date for the Annual Meeting represents a change of ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... Azur Pharma Limited ("Azur,Pharma") today announced that ... Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R),(carbidopa-levodopa orally ... Fluxid(TM) (famotidine orally,disintegrating tablets) from UCB (Euronext: ... Niravam, Parcopa and Kemstro ...
... The readers of The IN VIVO Blog , which ... device industries, have selected a Deal of the Year ... with Takeda Pharmaceuticals .More than 2,500 reader votes were cast ... start to finish among the 13 nominees selected by The ...
... (Nasdaq: MATK ) announced today that it will ... conference. The conference is being held January 14-15, 2009 ... Dana Point, California. Peter L. Buzy, Chief Financial Officer, ... 14, 2009 at 1:25 PM PT.A live audio webcast of ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of Medicine have just developed an advanced imaging technique ... or white blood cells. Microdomains are restricted areas on ... signaling molecules accumulate during cell activation. Using digital multi-channel ... subsets and their forming microdomains in the vascular system ...
... single-walled carbon nanotubes (SWCNTs) shorter than about 200 nanometers ... pose an increased risk to health, according to scientists ... The results of their laboratory studies appear in an ... uses ranging from electronic displays to fuel cells to ...
... of Michigan analytical chemist Kristina Hakansson sets the stage ... growing body of evidence points to assemblies of sugars ... as accomplices in the growth and spread of tumors. ... traditional analytical methods have not been sufficient. , ...
Cached Biology News:New imaging technique tracks traffic patterns of white blood cells 2Cells selectively absorb short nanotubes 2A sweet step toward new cancer therapies 2
Rab1A...
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: